Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2024-05-23 Proxy Solicitation & In…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'PRELIMINARY PROXY STATEMENT' and references Schedule 14A, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on, voting instructions, and other meeting logistics. The document is clearly a proxy solicitation material intended to inform shareholders and solicit their votes for the Annual Meeting. It is not the actual Annual Report, nor an announcement of voting results, nor a report of management or financial results. The presence of detailed proposals and voting instructions confirms this is a Proxy Solicitation & Information Statement filing. The document length (15,000 characters) and content confirm it is the proxy statement itself, not just a brief announcement or notice. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2024-05-23 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Cidara Therapeutics, Inc. It includes detailed information about the determination of annual bonuses for named executive officers for fiscal year 2023, including revised Summary Compensation Tables and Pay Versus Performance Tables. The content focuses on executive compensation updates and disclosures required by SEC regulations, specifically referencing Item 5.02(f) of Form 8-K. It is not a full annual report (10-K), nor is it a proxy statement or remuneration report (DEF 14A). The document is a regulatory filing providing updated executive compensation information outside of the annual proxy or annual report. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length and detail confirm it is not a brief announcement or certification but a substantive regulatory filing.
2024-05-20 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Cidara Therapeutics, Inc. It reports the issuance of a press release with financial results for the first quarter ended March 31, 2024. The document itself is a short report (3703 characters) that states the press release is attached as an exhibit and does not contain the full financial data or detailed analysis. According to the 'Menu vs Meal' rule, this is an announcement of financial results rather than the full earnings release document. The appropriate classification for such a document is Earnings Release (ER), as it announces quarterly financial results. Confidence is high because the document explicitly states it is reporting financial results for a quarter and includes a press release with those results.
2024-05-15 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q1 2024
2024-05-15 English
Regulatory Filings 2024
Regulatory Filings
2024-05-04 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 3, 2024. It primarily announces an update to a corporate slide presentation (Exhibit 99.1) that will be used in investor meetings. The text does not contain financial statements or detailed financial analysis but rather refers to an attached presentation. The document length is 3078 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements about presentations or reports that are attached or referenced but not included in full should be classified as Regulatory Filings (RNS). Therefore, this filing is best classified as a Regulatory Filing (RNS).
2024-05-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.